- Austin TX, US Linghua WANG - Houston TX, US Shaojun ZHANG - Houston TX, US Liang ZHANG - Houston TX, US Krystle NOMIE - Houston TX, US Makhdum AHMED - Houston TX, US Yixin YAO - Houston TX, US
Provided herein is a molecular signature that delineates response to ibrutinib and its use in predicting responsiveness to ibrutinib for lymphoma patients, and in particular for mantle cell lymphoma patients. Also provided are methods of treating a patient that is predicted to be ibrutinib-resistant with an inhibitor of oxidative phosphorylation, a BH3-mimetic, a noncovalent BTK inhibitor, or a CAR-T therapy.